Joseph Scarrott

Journal articles

• Wiseman JP, Scarrott JM, Alves-Cruzeiro J, Saffari A, Böger C, Karyka E, Dawes E, Davies AK, Marchi PM, Graves E , Fernandes F et al (2024) Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47. EMBO Molecular Medicine, 16(11), 2882-2917. View this article in WRRO
• Johari YB, Pohle TH, Whitehead J, Scarrott JM, Liu P, Mayer A & James DC (2024) Molecular design of controllable recombinant adeno‐associated virus (AAV) expression systems for enhanced vector production. Biotechnology Journal, 19(6). View this article in WRRO
• Scarrott JM, Alves-Cruzeiro J, Marchi PM, Webster CP, Yang Z-L, Karyka E, Marroccella R, Coldicott I, Thomas H & Azzouz M (2023) Ap4b1-knockout mouse model of hereditary spastic paraplegia type 47 displays motor dysfunction, aberrant brain morphology and ATG9A mislocalization. Brain Communications, 5(1).
• Scarrott JM, Johari YB, Pohle TH, Liu P, Mayer A & James DC (2022) Increased recombinant adeno‐associated virus production by HEK293 cells using small molecule chemical additives. Biotechnology Journal.
• Johari YB, Scarrott JM, Pohle TH, Liu P, Mayer A, Brown AJ & James DC (2022) Engineering of the CMV promoter for controlled expression of recombinant genes in HEK293 cells. Biotechnology Journal, 17(8).
• Johari YB, Jaffé SRP, Scarrott JM, Johnson AO, Mozzanino T, Pohle TH, Maisuria S, Bhayat‐Cammack A, Lambiase G, Brown AJ , Tee KL et al (2021) Production of trimeric SARS‐CoV‐2 spike protein by CHO cells for serological COVID‐19 testing. Biotechnology and Bioengineering, 118(2), 1013-1021. View this article in WRRO
• Behne R, Teinert J, Wimmer M, D’Amore A, Davies AK, Scarrott JM, Eberhardt K, Brechmann B, Chen IP-F, Buttermore ED , Barrett L et al (2020) Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking. Human Molecular Genetics, 29(2), 320-334.
• Iannitti T, Scarrott J, Likhite S, Coldicott IRP, Lewis KE, Heath PR, Higginbottom A, Myszczynska MA, Milo M, Hautbergue GM , Meyer K et al (2018) Translating SOD1 gene silencing towards the clinic: A highly efficacious, off-target free and biomarker-supported strategy for familial ALS. Molecular Therapy : Nucleic Acids, 12, 75-88. View this article in WRRO
• Scarrott JM, Herranz-Martín S, Alrafiah AR, Shaw PJ & Azzouz M (2015) Current developments in gene therapy for amyotrophic lateral sclerosis.. Expert Opinion on Biological Therapy. View this article in WRRO

Book chapters

• Chandran JS, Scarrott JM, Shaw P & Azzouz M (2017) Gene Therapy in the Nervous System: Failures and Successes In El-Khamisy S (Ed.), Personalised Medicine Lessons from Neurodegeneration to Cancer Springer
• Chandran JS, Scarrott JM, Shaw PJ & Azzouz M (2017) Gene Therapy in the Nervous System: Failures and Successes, Personalised Medicine (pp. 241-257). View this article in WRRO

Conference proceedings

• Wiseman J, Alves-Cruzeiro J, Scarrott JM, Karyka E, Marchi PM, Graves E, Webster CP, Yang Z, Coldicott I, Dawes E , Shaw PJ et al (2024) AAV9-mediated gene replacement therapy for spastic paraplegia 47. Human Gene Therapy, Vol. 35(3-4) (pp A181-A182). Brussels, Belgium, 24 October 2023 - 24 October 2023. View this article in WRRO
• Wiseman J, Cruzeiro J, Scarrott J, Karyka E, Marchi P, Webster CP, Yang Z, Coldicott I, Shaw PJ, Ferraiuolo L & Azzouz M (2022) Gene Replacement Therapy for Spastic Paraplegia 47. HUMAN GENE THERAPY, Vol. 33(23-24) (pp A26-A27)
• Scarrott JM, Johari YB, Pohle TH, Liu P, Mayer A & James DC (2022) Small molecule chemical additives for enhanced recombinant AAV production in HEK293 cells. HUMAN GENE THERAPY, Vol. 33(23-24) (pp A105-A105)
• Scarrott JM, Coldicott I, Davies A, Hirst J, Karyka E, Bauer C & Azzouz M (2019) Development of an AAV9-mediated gene therapy for hereditary spastic paraplegia 47. HUMAN GENE THERAPY, Vol. 30(8) (pp A18-A18)
• Scarrott J, Ferraiuolo L, Heath P, Gelsthorpe C, Kaspar B, Shaw DP & Azzouz M (2016) Investigating the Specificity of RNAi Molecules in Human Gene Therapy for Superoxide Dismutase 1-linked Familial Amyotrophic Lateral Sclerosis. HUMAN GENE THERAPY, Vol. 27(7) (pp A16-A17)

Patents

• Azzouz M, Scarrott J & Karyka E (2021) Gene Therapy Treatment. WO2021205028A1 Appl. 14 Oct 2021.

Preprints

• Scarrott J, Johari YB, Pohle T, Liu P, Mayer A & James D (2022) Increased recombinant AAV production by HEK293 cells using small molecule chemical additives, Wiley.
• Johari YB, Jaffé SRP, Scarrott JM, Johnson AO, Mozzanino T, Pohle TH, Maisuria S, Bhayat-Cammack A, Brown AJ, Tee KL , Jackson PJ et al (2020) Production of Trimeric SARS-CoV-2 Spike Protein by CHO Cells for Serological COVID-19 Testing, Cold Spring Harbor Laboratory.
• Johari Y, Jaffe S, Scarrott J, Johnson A, Mozzanino TO, Pohle T, Maisuria S, Cammack AB, Brown A, Tee KL , Jackson P et al (2020) Production of Trimeric SARS-CoV-2 Spike Protein by CHO Cells for Serological COVID-19 Testing, Wiley.
• Tee KL, Jackson PJ, Scarrott JM, Jaffe SRP, Johnson AO, Johari Y, Pohle TH, Mozzanino T, Price J, Grinham J , Brown A et al (2020) Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay, Cold Spring Harbor Laboratory.